Wall Street analysts expect Quest Diagnostics Inc (NYSE:DGX) to report earnings of $1.72 per share for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Quest Diagnostics’ earnings, with estimates ranging from $1.65 to $1.79. Quest Diagnostics reported earnings per share of $1.68 in the same quarter last year, which suggests a positive year over year growth rate of 2.4%. The company is expected to announce its next quarterly earnings results on Tuesday, October 22nd.

According to Zacks, analysts expect that Quest Diagnostics will report full year earnings of $6.50 per share for the current fiscal year, with EPS estimates ranging from $6.46 to $6.55. For the next fiscal year, analysts anticipate that the business will post earnings of $6.81 per share, with EPS estimates ranging from $6.78 to $6.90. Zacks’ EPS averages are an average based on a survey of research analysts that cover Quest Diagnostics.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, July 23rd. The medical research company reported $1.73 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.69 by $0.04. Quest Diagnostics had a net margin of 9.64% and a return on equity of 15.05%. The business had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter last year, the firm earned $1.75 earnings per share. The business’s revenue for the quarter was up 1.8% on a year-over-year basis.

A number of equities analysts have weighed in on DGX shares. Evercore ISI reaffirmed a “buy” rating and set a $108.00 target price on shares of Quest Diagnostics in a research note on Thursday, August 8th. Goldman Sachs Group downgraded shares of Quest Diagnostics from a “neutral” rating to a “sell” rating and decreased their target price for the company from $90.00 to $85.00 in a research note on Monday, July 15th. Mizuho set a $110.00 target price on shares of Quest Diagnostics and gave the company a “buy” rating in a research note on Monday, May 20th. Canaccord Genuity raised their target price on shares of Quest Diagnostics from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Finally, Credit Suisse Group raised their target price on shares of Quest Diagnostics from $99.00 to $105.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $105.06.

Several large investors have recently bought and sold shares of DGX. Pearl River Capital LLC purchased a new stake in shares of Quest Diagnostics during the second quarter valued at approximately $28,000. Wealthcare Advisory Partners LLC purchased a new stake in shares of Quest Diagnostics during the second quarter valued at approximately $29,000. Berman Capital Advisors LLC boosted its holdings in Quest Diagnostics by 47.7% in the second quarter. Berman Capital Advisors LLC now owns 319 shares of the medical research company’s stock worth $32,000 after purchasing an additional 103 shares during the last quarter. Penserra Capital Management LLC purchased a new stake in Quest Diagnostics in the first quarter worth approximately $42,000. Finally, Signaturefd LLC boosted its holdings in Quest Diagnostics by 74.7% in the first quarter. Signaturefd LLC now owns 505 shares of the medical research company’s stock worth $45,000 after purchasing an additional 216 shares during the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Shares of NYSE DGX traded up $1.04 on Friday, reaching $104.97. 1,206,128 shares of the company’s stock traded hands, compared to its average volume of 1,124,224. Quest Diagnostics has a 12 month low of $78.95 and a 12 month high of $109.05. The business’s 50 day simple moving average is $101.69 and its two-hundred day simple moving average is $96.55. The company has a market cap of $14.09 billion, a price-to-earnings ratio of 16.64, a price-to-earnings-growth ratio of 2.13 and a beta of 0.87. The company has a quick ratio of 0.77, a current ratio of 0.82 and a debt-to-equity ratio of 0.58.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.02%. The ex-dividend date of this dividend is Thursday, October 3rd. Quest Diagnostics’s payout ratio is 33.60%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Read More: How the Consumer Price Index (CPI) is calculated?

Get a free copy of the Zacks research report on Quest Diagnostics (DGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.